News Focus
News Focus
icon url

DewDiligence

11/25/19 4:14 PM

#227083 RE: DewDiligence #227059

NVS-MDCO slide #11: Inclisiran is patent-protected until 2035 (US) / 2036 (EU).
icon url

DewDiligence

11/25/19 8:11 PM

#227091 RE: DewDiligence #227059

NVS-MDCO addendum: The effective deal value is $9.0B (rather than the $9.7B nominal value) because MDCO has $200M in net cash and NVS will receive a $500M NPV tax benefit from MDCO’s NOLs (according to NVS’ CFO on today’s CC).
icon url

DewDiligence

01/06/20 11:52 AM

#228001 RE: DewDiligence #227059

NVS closes MDCO acquisition—only 6wks from announcement to consummation:

https://www.globenewswire.com/news-release/2020/01/06/1966217/0/en/Novartis-completes-tender-offer-for-all-outstanding-shares-of-The-Medicines-Company.html

For speed, a tender offer (with no shareholder vote) is the way to go.
icon url

DewDiligence

10/16/20 9:38 AM

#235153 RE: DewDiligence #227059

CHMP approves NVS’ Leqvio (inclisiran) for hypercholesterolemia or mixed dyslipidemia:

https://www.globenewswire.com/news-release/2020/10/16/2109800/0/en/Novartis-receives-positive-CHMP-opinion-for-Leqvio-inclisiran-a-potential-first-in-class-siRNA-for-the-treatment-of-high-cholesterol.html

Rubber-stamping by the European Commission will follow in 2-3 months.
icon url

DewDiligence

12/18/20 5:35 PM

#236365 RE: DewDiligence #227059